211 results on '"Anichini A"'
Search Results
2. 27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial
3. 123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study
4. 26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)
5. SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells
6. Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth
7. Treatment Intensification following Glucagon-Like Peptide-1 Receptor Agonist Treatment in Type 2 Diabetes: the RESTORE-G Real-World Study
8. SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
9. Evaluation of coumarin-tagged deferoxamine as a Zr(IV)-based PET/fluorescence dual imaging probe
10. Immunotherapy for brain metastases and primary brain tumors
11. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
12. 12P Multi-omics correlation with clinical outcome in metastatic melanoma patients treated with ipilimumab plus guadecitabine: The NIBIT-M4 study
13. A sub-analysis of the SAGE study in Italy indicates good glycemic control in type 1 diabetes
14. Evaluation of coumarin-tagged deferoxamine as a Zr(IV)-based PET/fluorescence dual imaging probe
15. SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells
16. SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
17. Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins
18. Physician experts in diabetes are natural team leaders for managing diabetic patients with foot complications. A position statement from the Italian diabetic foot study group
19. Adaptive plasticity of bushcricket acoustic signalling in socially heterogeneous choruses
20. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
21. 12P Multi-omics correlation with clinical outcome in metastatic melanoma patients treated with ipilimumab plus guadecitabine: The NIBIT-M4 study
22. Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum
23. How long can SARS-CoV-2 persist in human corpses?
24. The automatic recognition of ceramics from only one photo: The ArchAIDE app
25. To compete or not to compete: bushcricket song plasticity reveals male body condition and rival distance
26. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes)
27. Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?
28. Physicochemical properties and sorption capacities of sawdust-based biochars and commercial activated carbons towards ethoxylated alkylphenols and their phenolic metabolites in effluent wastewater from a textile district
29. Physician experts in diabetes are natural team leaders for managing diabetic patients with foot complications. A position statement from the Italian diabetic foot study group
30. Anticancer innovative therapy: Highlights from the ninth annual meeting
31. Adaptive plasticity of bushcricket acoustic signalling in socially heterogeneous choruses
32. Hospitalization for Charcot neuroarthropathy in diabetes: A population study in Italy
33. Gender difference in diabetes related excess risk of cardiovascular events: When does the ‘risk window’ open?
34. The automatic recognition of ceramics from only one photo: The ArchAIDE app
35. Physicochemical properties and sorption capacities of sawdust-based biochars and commercial activated carbons towards ethoxylated alkylphenols and their phenolic metabolites in effluent wastewater from a textile district
36. Assessment of cutaneous microcirculation by laser Doppler flowmetry in type 1 diabetes
37. First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)
38. Comparison between four tropical wood species for their resistance to marine borers (Teredo spp and Limnoria spp) in the Strait of Messina
39. Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke
40. The role of joint mobility in evaluating and monitoring the risk of diabetic foot ulcer
41. New technologies for plant food processing in the Gravettian
42. Endoscopic extradural anterior clinoidectomy and optic nerve decompression through a pterional port
43. First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)
44. MA04.06 PD-1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody-Fc/FcR Interaction
45. Comprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC)
46. To compete or not to compete: bushcricket song plasticity reveals male body condition and rival distance
47. Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: The open-label, single-arm, phase 2 ARCADIA trial
48. Peculiar: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC)
49. Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum
50. Pembrolizumab as Neoadjuvant Therapy Preceding Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Group, Phase 2 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.